ipar-20250930.htm

5

4

6

3.3

false

Q3

NY

2025

--12-31

0000822663

false

false

false

false

0000822663
2023-12-31
0000822663
2024-07-01
2024-09-30
0000822663
2024-01-01
2024-09-30
0000822663
2025-01-01
2025-09-30
0000822663
2025-09-30
0000822663
2024-12-31
0000822663
2022-12-31
0000822663
2021-04-30
0000822663
ipar:MaisonGoutalMember
ipar:AmorepacificEuropeMember
2025-03-01
2025-03-31
0000822663
ipar:EmployeesMember
ipar:InterparfumsSAMember
2025-01-01
2025-09-30
0000822663
srt:MaximumMember
us-gaap:EmployeeStockOptionMember
2025-01-01
2025-09-30
0000822663
srt:MinimumMember
us-gaap:EmployeeStockOptionMember
2025-01-01
2025-09-30
0000822663
ipar:RochasFashionMember
us-gaap:TrademarksMember
2021-01-01
2021-03-31
0000822663
ipar:RochasFashionMember
us-gaap:TrademarksMember
2024-10-01
2024-12-31
0000822663
ipar:EuropeanBasedOperationsMember
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0000822663
srt:GeographyEliminationsMember
ipar:EuropeanBasedOperationsMember
2024-01-01
2024-09-30
0000822663
srt:GeographyEliminationsMember
ipar:UnitedStatesBasedOperationsMember
2024-01-01
2024-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:EuropeanBasedOperationsMember
2024-01-01
2024-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:UnitedStatesBasedOperationsMember
2024-01-01
2024-09-30
0000822663
us-gaap:OperatingSegmentsMember
ipar:EuropeanBasedOperationsMember
2025-01-01
2025-09-30
0000822663
us-gaap:OperatingSegmentsMember
ipar:UnitedStatesBasedOperationsMember
2025-01-01
2025-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:EuropeanBasedOperationsMember
2025-01-01
2025-09-30
0000822663
srt:GeographyEliminationsMember
ipar:EuropeanBasedOperationsMember
2025-01-01
2025-09-30
0000822663
srt:GeographyEliminationsMember
ipar:UnitedStatesBasedOperationsMember
2025-01-01
2025-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:UnitedStatesBasedOperationsMember
2025-01-01
2025-09-30
0000822663
ipar:RochasFashionMember
us-gaap:TrademarksMember
2024-12-31
0000822663
ipar:RochasFashionMember
us-gaap:TrademarksMember
2022-12-31
0000822663
ipar:RochasFashionMember
us-gaap:TrademarksMember
2022-10-01
2022-12-31
0000822663
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0000822663
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0000822663
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0000822663
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel1Member
2024-12-31
0000822663
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel2Member
2024-12-31
0000822663
us-gaap:FairValueMeasurementsRecurringMember
us-gaap:FairValueInputsLevel3Member
2024-12-31
0000822663
ipar:InterparfumsSASubsidiaryMember
ipar:EmployeesMember
2025-01-01
2025-09-30
0000822663
ipar:InterparfumsSAMember
2024-12-31
0000822663
ipar:VanCleefAndArpelsMember
2024-01-01
2024-12-31
0000822663
ipar:CoachMember
2025-03-01
2025-03-31
0000822663
ipar:FierceFragranceMember
2025-03-01
2025-03-31
0000822663
ipar:AbercrombieFitchAndHollisterMember
2025-03-01
2025-03-31
0000822663
ipar:InterparfumsSAMember
2025-09-30
0000822663
us-gaap:EmployeeStockOptionMember
2024-01-01
2024-09-30
0000822663
us-gaap:EmployeeStockOptionMember
2025-01-01
2025-09-30
0000822663
ipar:EliminationsMember
2024-12-31
0000822663
ipar:EliminationsMember
2025-09-30
0000822663
ipar:EuropeanBasedOperationsMember
2024-12-31
0000822663
ipar:UnitedStatesBasedOperationsMember
2024-12-31
0000822663
ipar:EuropeanBasedOperationsMember
2025-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
2025-09-30
0000822663
ipar:EuropeanBasedOperationsMember
2024-01-01
2024-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
2024-01-01
2024-09-30
0000822663
srt:GeographyEliminationsMember
2024-01-01
2024-09-30
0000822663
srt:ReportableGeographicalComponentsMember
2024-01-01
2024-09-30
0000822663
ipar:EuropeanBasedOperationsMember
2025-01-01
2025-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
2025-01-01
2025-09-30
0000822663
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000822663
srt:ReportableGeographicalComponentsMember
2025-01-01
2025-09-30
0000822663
srt:GeographyEliminationsMember
2025-01-01
2025-09-30
0000822663
us-gaap:CommonStockMember
2023-12-31
0000822663
us-gaap:NoncontrollingInterestMember
2023-12-31
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31
0000822663
us-gaap:RetainedEarningsMember
2023-12-31
0000822663
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0000822663
ipar:VanCleefAndArpelsMember
2025-01-01
2025-09-30
0000822663
us-gaap:NoncontrollingInterestMember
2024-07-01
2024-09-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-07-01
2024-09-30
0000822663
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0000822663
ipar:LacosteMember
2025-01-01
2025-09-30
0000822663
us-gaap:CommonStockMember
2024-12-31
0000822663
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0000822663
us-gaap:RetainedEarningsMember
2024-12-31
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-12-31
0000822663
us-gaap:NoncontrollingInterestMember
2024-12-31
0000822663
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-09-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-09-30
0000822663
us-gaap:RetainedEarningsMember
2025-01-01
2025-09-30
0000822663
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-01-01
2025-09-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01
2024-09-30
0000822663
us-gaap:NoncontrollingInterestMember
2025-01-01
2025-09-30
0000822663
us-gaap:NoncontrollingInterestMember
2024-01-01
2024-09-30
0000822663
us-gaap:CommonStockMember
2025-09-30
0000822663
us-gaap:CommonStockMember
2024-06-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2025-09-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0000822663
us-gaap:RetainedEarningsMember
2025-09-30
0000822663
us-gaap:RetainedEarningsMember
2024-06-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-09-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-30
0000822663
us-gaap:NoncontrollingInterestMember
2025-09-30
0000822663
us-gaap:NoncontrollingInterestMember
2024-06-30
0000822663
ipar:RobertoCavalliMember
2025-01-01
2025-09-30
0000822663
us-gaap:FairValueMeasurementsRecurringMember
2025-09-30
0000822663
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0000822663
us-gaap:InterestRateSwapMember
2021-04-30
0000822663
us-gaap:ForeignExchangeContractMember
2025-09-30
0000822663
us-gaap:ForeignExchangeContractMember
2025-01-01
2025-09-30
0000822663
us-gaap:TreasuryStockCommonMember
2024-12-31
0000822663
us-gaap:TreasuryStockCommonMember
2023-12-31
0000822663
us-gaap:TreasuryStockCommonMember
2024-06-30
0000822663
us-gaap:TreasuryStockCommonMember
2025-09-30
0000822663
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0000822663
ipar:InterparfumsSAMember
2025-03-31
0000822663
ipar:InterparfumsSASubsidiaryMember
ipar:EmployeesMember
2022-03-31
0000822663
ipar:LongchampMember
ipar:InterparfumsSAMember
2025-07-01
2025-07-31
0000822663
ipar:InterparfumsSAMember
ipar:LongchampMember
2025-07-31
0000822663
us-gaap:TreasuryStockCommonMember
2025-01-01
2025-09-30
0000822663
us-gaap:TreasuryStockCommonMember
2024-01-01
2024-09-30
0000822663
2025-07-01
2025-09-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0000822663
us-gaap:RetainedEarningsMember
2025-06-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-30
0000822663
us-gaap:TreasuryStockCommonMember
2025-06-30
0000822663
us-gaap:NoncontrollingInterestMember
2025-06-30
0000822663
us-gaap:TreasuryStockCommonMember
2024-07-01
2024-09-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0000822663
us-gaap:RetainedEarningsMember
2024-09-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-09-30
0000822663
us-gaap:TreasuryStockCommonMember
2024-09-30
0000822663
us-gaap:NoncontrollingInterestMember
2024-09-30
0000822663
2024-09-30
0000822663
us-gaap:AdditionalPaidInCapitalMember
2025-07-01
2025-09-30
0000822663
us-gaap:RetainedEarningsMember
2025-07-01
2025-09-30
0000822663
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-07-01
2025-09-30
0000822663
us-gaap:TreasuryStockCommonMember
2025-07-01
2025-09-30
0000822663
us-gaap:NoncontrollingInterestMember
2025-07-01
2025-09-30
0000822663
us-gaap:CommonStockMember
2025-06-30
0000822663
ipar:InterparfumsSAMember
2022-03-31
0000822663
srt:ReportableGeographicalComponentsMember
ipar:UnitedStatesBasedOperationsMember
2025-07-01
2025-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:EuropeanBasedOperationsMember
2025-07-01
2025-09-30
0000822663
srt:ReportableGeographicalComponentsMember
2025-07-01
2025-09-30
0000822663
srt:GeographyEliminationsMember
ipar:UnitedStatesBasedOperationsMember
2025-07-01
2025-09-30
0000822663
srt:GeographyEliminationsMember
ipar:EuropeanBasedOperationsMember
2025-07-01
2025-09-30
0000822663
srt:GeographyEliminationsMember
2025-07-01
2025-09-30
0000822663
us-gaap:OperatingSegmentsMember
ipar:UnitedStatesBasedOperationsMember
2025-07-01
2025-09-30
0000822663
us-gaap:OperatingSegmentsMember
ipar:EuropeanBasedOperationsMember
2025-07-01
2025-09-30
0000822663
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
2025-07-01
2025-09-30
0000822663
ipar:EuropeanBasedOperationsMember
2025-07-01
2025-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:UnitedStatesBasedOperationsMember
2024-07-01
2024-09-30
0000822663
srt:GeographyEliminationsMember
ipar:UnitedStatesBasedOperationsMember
2024-07-01
2024-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0000822663
ipar:UnitedStatesBasedOperationsMember
2024-07-01
2024-09-30
0000822663
srt:ReportableGeographicalComponentsMember
ipar:EuropeanBasedOperationsMember
2024-07-01
2024-09-30
0000822663
srt:GeographyEliminationsMember
ipar:EuropeanBasedOperationsMember
2024-07-01
2024-09-30
0000822663
ipar:EuropeanBasedOperationsMember
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0000822663
ipar:EuropeanBasedOperationsMember
2024-07-01
2024-09-30
0000822663
srt:ReportableGeographicalComponentsMember
2024-07-01
2024-09-30
0000822663
srt:GeographyEliminationsMember
2024-07-01
2024-09-30
0000822663
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0000822663
srt:MaximumMember
ipar:EmployeesMember
ipar:InterparfumsSAMember
2022-03-01
2022-03-31
0000822663
ipar:EmployeesMember
ipar:InterparfumsSAMember
2025-06-01
2025-06-30
0000822663
2025-11-05
xbrli:shares
xbrli:pure
iso4217:EUR
iso4217:USD
iso4217:USD
xbrli:shares
ipar:Number

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

FORM

10-Q

(MARK
ONE)

☒

Quarterly Report pursuant
    to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended 
September 30, 2025
.

OR

☐

Transition Report pursuant
    to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ___________to ________.

Commission
File No. 
0-16469

INTERPARFUMS, INC.

 (Exact
name of registrant as specified in its charter)

Delaware

13-3275609

(State or other jurisdiction
    of

(I.R.S. Employer

incorporation or
    organization)

Identification No.)

551 Fifth Avenue
, 
New York
, 
New York

10176

(Address of Principal Executive Offices)          (Zip Code)

(212)

983-2640

(Registrants telephone
    number, including area code)

Securities
registered pursuant to Section 12(b) of the Act:

Title
    of each class

Trading
    Symbol(s)

Name
    of each exchange on which registered

Common Stock, $.001 par value per share

IPAR

The Nasdaq Stock Market

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days: 
Yes

☒
 No ☐

Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).

Yes

☒
 No 
☐

Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act).

Large
    accelerated filer
 ☒

Accelerated
    filer ☐

Non-accelerated
    filer ☐ (Do not check if a smaller reporting company)

Smaller
    reporting company 
☐

Emerging
    Growth company 
☐

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 
☐

No

☒

Indicate
the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

At

November 5, 2025
, there were 
32,064,728
 shares of common stock, par value $.001 per share, outstanding.

INTERPARFUMS, INC. AND SUBSIDIARIES

INDEX

​

 Page Number 

Part I.

Financial Information

1

Item 1.

Financial
                                         Statements

1

Consolidated Balance Sheets as of 
September 30, 2025
 and 
December 31, 2024

2

Consolidated Statements of Income for the 
Three and Nine
 Months Ended 
September 30, 2025
 and 
September 30, 2024

3

Consolidated Statements of Comprehensive Income for the 
Three and Nine
 Months Ended 
September 30, 2025
 and 
September 30, 2024

4

Consolidated Statements of Changes in Equity for the 
Three and Nine
 Months Ended 
September 30, 2025
 and 
September 30, 2024

5

Consolidated Statements of Cash Flows for the 
Nine Months Ended September 30, 2025
 and 
September 30, 2024

6

Notes
to Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

17

Item 4.

Controls and Procedures

17

Part II.

Other Information

26

Item 1A.

Risk Factors

26

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

26

Item 5.

Other Information

26

Item 6.

Exhibits.

27

SIGNATURES

28

​

INTERPARFUMS, INC. AND SUBSIDIARIES

Part
I. Financial Information

Item

                          1.

Financial
                                         Statements

In
our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring
adjustments) necessary to present fairly our financial position, results of operations and cash flows for the interim periods
presented. We have condensed such financial statements in accordance with the rules and regulations of the Securities and Exchange
Commission (“SEC”). Therefore, such financial statements do not include all disclosures required by accounting principles
generally accepted in the United States of America. In preparing these consolidated financial statements, the Company has evaluated
events and transactions for potential recognition or disclosure through the date the consolidated financial statements were issued
by filing with the SEC. These financial statements should be read in conjunction with our audited financial statements for the
year ended 
December 31, 2024
, included in our annual report filed on Form 10-K.

The
results of operations for the 
nine months ended September 30, 2025
, are not necessarily indicative of the results to be expected
for the entire fiscal year.

Page 
1

INTERPARFUMS, INC. AND SUBSIDIARIES

CONSOLIDATED
BALANCE SHEETS

 (In
thousands except share and per share data)

(Unaudited)

ASSETS

September 30, 2025

December 31, 2024

Current assets:

Cash and cash equivalents

$

110,396

$

125,433

Short-term investments

77,460

109,311

Accounts receivable, net

363,624

274,705

Inventories

388,302

371,920

Receivables, other

10,369

6,122

Other current assets

40,587

27,035

Income taxes receivable

—

306

Total current assets

990,738

914,832

Property, equipment and leasehold improvements, net

186,206

153,773

Right-of-use assets, net

24,558

24,603

Trademarks, licenses and other intangible assets, net

328,220

282,484

Deferred tax assets

15,262

17,034

Other assets

19,666

18,535

Total assets

$

1,564,650

$

1,411,261

LIABILITIES AND EQUITY

Current liabilities:

Loans payable - banks

$

9,393

$

8,311

Current portion of long-term debt

56,901

41,607

Current portion of lease liabilities

6,193

6,087

Accounts payable – trade

66,985

91,049

Accrued expenses

152,624

172,758

Income taxes payable

10,677

12,615

Total current liabilities

302,773

332,427

Long–term debt, less current portion

139,976

115,734

Lease liabilities, less current portion

17,406

20,455

Equity:

Interparfums, Inc. shareholders’ equity:

Preferred stock, $
.001
 par;
    authorized 
1,000,000
 shares; 
none
 issued

—

—

Common
stock, $
.001
 par; authorized 
100,000,000
 shares; outstanding 
32,064,728
 and 
32,110,170
 shares at 
September 30, 2025
 and 
December 31, 2024
, respectively

32

32

Additional paid-in capital

109,006

106,702

Retained earnings

826,964

763,240

Accumulated other comprehensive loss

(
4,780

)

(
72,239

)

Treasury stock, at cost, 
8,960,587
 and 
9,981,665
 shares at 
September 30, 2025
 and 
December 31, 2024
, respectively

(
60,335

)

(
52,864

)

Total Interparfums, Inc. shareholders’ equity

870,887

744,871

Noncontrolling interest

233,608

197,774

Total equity

1,104,495

942,645

Total liabilities and equity

$

1,564,650

$

1,411,261

See
notes to consolidated financial statements.

Page 
2

INTERPARFUMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands except per share data)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Net sales

$

429,579

$

424,629

$

1,102,334

$

1,090,821

Cost of sales

156,762

153,469

392,451

396,519

Gross margin

272,817

271,160

709,883

694,302

Selling, general and administrative expenses

164,261

165,166

467,074

455,506

Income from operations

108,556

105,994

242,809

238,796

Other expenses (income):

Interest expense

2,305

1,978

5,637

5,726

Loss on foreign currency

2,215

3,355

4,576

3,085

Interest and investment (income) loss

(
2,547

)

254

(
1,199

)

(
1,690

)

Other (income) loss

(
978

)

1

(
1,302

)

(
35

)

Nonoperating Income (Expense)

995

5,588

7,712

7,086

Income before income taxes

107,561

100,406

235,097

231,710

Income taxes

24,282

23,571

55,218

54,974

Net income

83,279

76,835

179,879

176,736

Less:  Net income attributable to the noncontrolling interest

17,470

14,576

39,590

36,606

Net income attributable to Interparfums, Inc.

$

65,809

$

62,259

$

140,289

$

140,130

Earnings per share:

Net income attributable to Interparfums, Inc. common shareholders:

Basic

$

2.05

$

1.94

$

4.37

$

4.37

Diluted

$

2.05

$

1.93

$

4.36

$

4.34

Weighted average number of shares outstanding: 

Basic

32,113

32,026

32,114

32,030

Diluted

32,149

32,266

32,158

32,266

Dividends declared per share

$

0.80

$

0.75

$

2.40

$

2.25

See notes to consolidated financial statements.

Page 
3

INTER
PARFUMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 (In thousands)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Comprehensive income:

Net income

$

83,279

$

76,835

$

179,879

$

176,736

Other comprehensive income:

Net derivative instrument (loss) gain, net of tax 

(
5,540

)

(
239

)

965

(
1,411

)

Transfer from OCI into earnings 

—

—

1,631

(
64

)

Pension benefits, net of tax

(
51

)

—

(
153

)

—

Translation adjustments, net of tax 

834

31,385

87,936

10,891

Comprehensive income

78,522

107,981

270,258

186,152

Comprehensive income attributable to the noncontrolling interests:

Net income

17,470

14,576

39,590

36,606

Other comprehensive income:

Net derivative instrument (loss) gain, net of tax 

(
1,522

)

(
66

)

271

(
388

)

Pension benefits, net of tax

(
14

)

—

(
43

)

—

Translation adjustments, net of tax

(
40

)

8,989

22,692

2,257

Comprehensive income attributable to the noncontrolling interests

15,894

23,499

62,510

38,475

Comprehensive income attributable to Interparfums, Inc.

$

62,628

$

84,482

$

207,748

$

147,677

See notes to consolidated financial statements.

Page 
4

INTERPARFUMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

 (In thousands)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Common stock, beginning and end of period

$

32

$

32

$

32

$

32

Additional paid-in capital, beginning of period

108,802

100,505

106,702

98,565

Shares issued upon exercise of stock options

—

359

2,112

1,729

Share-based compensation

204

259

615

780

Purchase/Transfer of subsidiary shares 

—

—

(
423

)

49

Additional paid-in capital, end of period

109,006

101,123

109,006

101,123

Retained earnings, beginning of period

787,031

724,268

763,240

693,848

Net income

65,809

62,259

140,289

140,130

Dividends

(
25,695

)

(
24,022

)

(
77,089

)

(
71,985

)

Share-based compensation

(
181

)

321

524

833

Retained earnings, end of period

826,964

762,826

826,964

762,826

Accumulated other comprehensive loss, beginning of period

(
1,599

)

(
54,864

)

(
72,239

)

(
40,188

)

Foreign currency translation adjustment, net of tax

874

22,396

65,244

8,634

Transfer from other comprehensive income into earnings

—

—

1,631

(
64

)

Pension benefits, net of tax

(
37

)

—

(
110

)

—

Net derivative instrument gain (loss), net of tax

(
4,018

)

(
173

)

694

(
1,023

)

Accumulated other comprehensive loss, end of period

(
4,780

)

(
32,641

)

(
4,780

)

(
32,641

)

Treasury stock, beginning of period

(
54,907

)

(
52,864

)

(
52,864

)

(
52,864

)

    Shares repurchased

(
5,428

)

—

(
7,471

)

—

Treasury stock, end of period

(
60,335

)

(
52,864

)

(
60,335

)

(
52,864

)

Noncontrolling interest, beginning of period

217,393

184,129

197,774

192,777

Net income

17,470

14,576

39,590

36,606

Foreign currency translation adjustment, net of tax

(
40

)

8,989

22,692

2,257

Pension benefits, net of tax

(
14

)

—

(
43

)

—

Net derivative instrument gain (loss), net of tax

(
1,522

)

(
66

)

271

(
388

)

Share-based compensation

321

47

199

179

Transfer of subsidiary shares purchased

—

—

—

(
49

)

Dividends

—

(
1,022

)

(
26,875

)

(
24,729

)

Noncontrolling interest, end of period

233,608

206,653

233,608

206,653

Total equity

$

1,104,495

$

985,129

$

1,104,495

$

985,129

See notes to consolidated financial statements.

Page 
5

INTERPARFUMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Nine Months Ended

September 30,

2025

2024

Cash flows from operating activities:

Net income

$

179,879

$

176,736

Adjustments to reconcile net income to net cash used in operating activities:

Depreciation and amortization

18,836

18,201

Provision for doubtful accounts

1,716

613

Noncash stock compensation

1,313

1,768

Share of income of equity investment

(
673

)

(
109

)

Noncash lease expense

4,809

4,533

Deferred tax provision

3,454

(
4,909

)

Change in fair value of derivatives

(
7,064

)

(
153

)

Changes in:

Accounts receivable

 (
62,901

)

(
102,576

)

Inventories

18,749

(
35,237

)

Other assets

(
4,035

)

3,770

Operating lease liabilities

(
5,037

)

(
4,378

)

Accounts payable and accrued expenses

(
77,469

)

(
17,571

)

Income taxes, net

(
3,204

)

8,993

Net cash provided by operating activities

68,373

49,681

Cash flows from investing activities:

Purchases of short-term investments

(
93,244

)

(
146,868

)

Proceeds from sale of short-term investments

137,150

162,176

Purchases of property, equipment and leasehold improvements

(
22,866

)

(
2,889

)

Payment for intangible assets acquired

(
22,882

)

(
850

)

Net cash (used in) provided by investing activities

(
1,842

)

11,569

Cash flows from financing activities:

Proceeds from loans payable, bank

—

4,348

Proceeds of issuance of long-term debt

55,940

43,484

Repayment of long-term debt

(
37,046

)

(
24,781

)

Proceeds from exercise of options

2,112

1,729

Dividends paid

(
77,089

)

(
71,985

)

Dividends paid to noncontrolling interest

(
26,875

)

(
24,729

)

Purchase of subsidiary shares from noncontrolling interests

(
423

)

—

Purchase of treasury stock

(
7,471

)

—

Net cash used in financing activities

(
90,852

)

(
71,934

)

Effect of exchange rate changes on cash

9,284

641

 Net decrease in cash and cash equivalents 

(
15,037

)

(
10,043

)

Cash and cash equivalents - beginning of period

125,433

88,462

Cash and cash equivalents - end of period

$

110,396

$

78,419

Supplemental disclosure of cash flow information:

Cash paid for:

Interest

$

4,993

$

6,578

Income taxes

55,948

48,643

See notes to consolidated financial statements. 

Page 
6

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes
to Consolidated Financial Statements

(Unaudited) 

1.

Significant
                                         Accounting Policies:

The
accounting policies we follow are set forth in the notes to our consolidated financial statements included in our Form 10-K, which
was filed with the Securities and Exchange Commission for the year ended 
December 31, 2024
.

2.

Recent Agreements:

Longchamp

In July 2025, we announced that our 
72
% owned French subsidiary, Interparfums SA, signed an exclusive license agreement with Longchamp, a Parisian Maison, through 
December 31, 2036
. Interparfums SA will be responsible for the creation, development, production and distribution of fragrance lines in Longchamp-brand points of sale and selective distribution channels. The first launch is expected in 2027. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry.  

Goutal

In March 2025, we announced that our 
72
% owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Maison Goutal held by Amorepacific Europe. Amorepacific Europe will continue to operate the Goutal brand under an existing license agreement that expires on 
December 31, 2025
, when Interparfums SA will begin commercial use of the fragrance brand. 

Coach

In 
2015
, Coach and Interparfums SA signed an exclusive worldwide license agreement for the creation, the manufacturing and the distribution of fragrances under the Coach brand until June 30, 2026. In March 2025, the license agreement was renewed for an additional 
5
-year
 term, extending the license through 
June 30, 2031
. 

Abercrombie & Fitch and Hollister

In March 2025, we expanded our 
Fierce
 distribution agreement, which now allows for a global distribution of the iconic 
Fierce 
fragrance line that either party may terminate on 
two year
’s notice. Furthermore, our existing
 Abercrombie & Fitch and Hollister fragrance license agreement will expire on

March 14, 2028
.
 The goal of the updated 
Fierce
 distribution agreement is to drive, over time, more consistency between the products that are carried in the Abercrombie & Fitch stores and unaffiliated retailers. 

Off-White

In December 2024, we announced that our 
72
% owned French subsidiary, Interparfums SA, signed for all Off-White® brand names and registered trademarks for Class 
3
 fragrance and cosmetic products, subject to an existing license that expires on December 31, 2025, when Interparfums SA will begin commercial use of the fragrance brand. 

Van Cleef & Arpels

In 
2006
, Van Cleef & Arpels and Interparfums SA signed a 
12
-year worldwide license agreement to manufacture and distribute perfumes and related products under the Van Cleef & Arpels brand name, which was subsequently extended for a further 
six years
 until December 31, 2024. In December 2024, the license agreement was renewed for an additional 
9
-year term, through December 31, 2033. 

Roberto Cavalli

In July 2023, we closed a transaction agreement with Roberto Cavalli, whereby an exclusive and worldwide license was granted for the production and distribution of Roberto Cavalli brand perfumes and fragrance related products. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. 
The license became effective in July 2023 and will last for 
6.5
 years.
 We began shipping Roberto Cavalli perfumes and fragrance related products in February 2024.

Page 
7

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

Lacoste

In December 2022, we closed a transaction agreement with Lacoste, whereby an exclusive and worldwide license was granted for the production and distribution of Lacoste brand perfumes and cosmetics. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. 
The license became effective in January 2024 and will last for 
15
 years
. We began shipping Lacoste fragrances in January 2024.

Dunhill

The Dunhill fragrance license expired on September 30, 2023 and was not renewed. The Company had a 
twelve
-month sell-off period during which it maintained the right to sell-off remaining Dunhill fragrance inventory, which is customary in the fragrance industry. As of September 30, 2024, all finished goods and components have been sold and we no longer carry any inventory related to Dunhill. 

Rochas Fashion

As a result of operational challenges faced by the Rochas Fashion business, we took a $
2.4
 million impairment charge on our Rochas fashion trademark in the first quarter of 
2021
 and a $
6.8
 million impairment charge in the fourth quarter of 
2022
 after management reviewed and agreed with an independent expert's conclusion that the fair value of the trademark was $
11.2
 million. In 
2023
, the Rochas team underwent a strategic shift to take over their own brand operations, exiting contracts with manufacturers and distributors to make this new structure operational beginning in 
2024
. In the fourth quarter of 
2024
, we again took a $
4.0
 million impairment charge on the Rochas fashion trademark after management reviewed and agreed with an independent expert's conclusion that the fair value of the trademark was $
7.2
 million. There have been no triggering events through the first three quarters
 of 
2025
 that would require management to perform an impairment analysis. 

3.

Recent
                                         Accounting Pronouncements:

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.

2024
-
03
, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic

220-40
): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No.

2025
-
01
, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic

220
-
40
): Clarifying the Effective Date, which clarified the effective date of ASU

2024
-
03
. The ASU requires, among other things, more detailed disclosures about types of expenses in commonly presented expense captions such as cost of sales and selling, general and administrative expenses and is intended to improve the disclosures about an entity's expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization. ASU

2024
-
03

will also require the Company to disclose both the amount and the Company's definition of selling expenses. The guidance, as clarified by ASU

2025
-
01
, is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, on a prospective or retrospective basis. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes
(Topic 740): Improvements to Income Tax Disclosures. The ASU includes
amendments requiring enhanced income tax disclosures, primarily related to
standardization and disaggregation of rate reconciliation categories and income
taxes paid by jurisdiction. The guidance is effective for annual periods
beginning after December 15, 2024. Early adoption is permitted and shall be
applied on a prospective basis with the option to apply retrospectively. We are
currently evaluating the impact of adopting this ASU on our disclosures.

There are no other recent accounting pronouncements issued but not yet
adopted that would have a material effect on our consolidated financial
statements.

4.

Inventories:

Inventories consist of the following:

(In thousands)

September 30, 2025

December 31, 2024

Raw materials and component parts

$

123,421

$

137,572

Finished goods

264,881

234,348

$

388,302

$

371,920

Page 
8

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

5.

Fair Value Measurement:

The following tables present our financial assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. 
The fair value hierarchy has 
three
 levels based on the reliability of the inputs used to determine fair value.

Fair Value Measurements at 
September 30, 2025

Total

Quoted Prices in
 Active Markets for
 Identical Assets
 (Level 
1
)

Significant Other
 Observable
 Inputs
 (Level 
2
)

Significant
 Unobservable
 Inputs
 (Level 
3
)

Assets:

Short-term investments

$

77,460

$

3,579

$

73,881

$

—

Interest rate swaps

1,603

—

1,603

—

Foreign currency forward exchange contracts not accounted for using hedge 
accounting

6,911

—

6,911

—

Foreign currency forward exchange contracts accounted for using hedge accounting

—

—

—

—

Total Assets

$

85,974

$

3,579

$

82,395

$

—

Fair Value Measurements at 
December 31, 2024

Total

Quoted Prices in
 Active Markets for
 Identical Assets
 (Level 
1
)

Significant Other
 Observable
 Inputs
 (Level 
2
)

Significant
 Unobservable
 Inputs
 (Level 
3
)

Assets:

Short-term investments

$

109,311

$

7,703

$

101,608

$

—

Interest rate swaps

1,967

—

1,967

—

Total Assets

$

111,278

$

7,703

$

103,575

$

—

Liabilities:

Foreign currency forward exchange contracts not accounted for using hedge accounting

445

—

445

—

Foreign currency forward exchange contracts accounted for using hedge accounting

1,435

—

1,435

—

Total Liabilities

$

1,880

$

—

$

1,880

$

—

Page 
9

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

The carrying amount of cash and cash equivalents, short-term investments including money market funds and marketable equity securities, accounts receivable, other receivables, accounts payable and accrued expenses approximate fair value due to the short terms to maturity of these instruments. The carrying amount of loans payable approximates fair value as the interest rates on the Company’s indebtedness approximate current market rates. The fair value of the Company’s long-term debt was estimated based on the current rates offered to companies for debt with the same remaining maturities and is approximately equal to its carrying value.

Foreign currency forward exchange contracts are valued based on quotations from financial institutions and the value of interest rate swaps is the discounted net present value of the swaps using third party quotes from financial institutions.

6.

Derivative
                                         Financial Instruments:

The
Company enters into fo
reign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign
currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Before entering
into a derivative transaction for hedging purposes, we determine that a high degree of initial effectiveness exists between
the change in value of the hedged item and the change in the value of the derivative instrument from movement in exchange rates.
High effectiveness means that the change in the cash flows of the derivative instrument will effectively offset the change in
the cash flows of the hedged item. The effectiveness of each hedged item is measured throughout the hedged period and is based
on the dollar offset methodology and excludes the portion of the fair value of the foreign currency forward exchange contract
attributable to the change in spot-forward difference which is reported in current period earnings. Any hedge ineffectiveness
is also recognized as a gain or loss on foreign currency in the income statement. For contracts designated as hedges that are no longer deemed
highly effective, hedge accounting is discontinued, and gains and losses accumulated in other comprehensive income are reclassified
to earnings. If it is probable that the forecasted transaction will no longer occur, then any gains or losses accumulated
in other comprehensive income are reclassified to current-period earnings. 

In
December 2022, to finance the acquisition of the Lacoste trademark, the Company entered into a €
50
 million (approximately
$
58.7
 million
) 
4
-year term loan with a variable interest rate. This variable rate debt was swapped for variable interest rate
debt with a maximum rate of 
2
% per annum. This swap is a hedged derivative instrument and is therefore recorded at fair value
and changes in fair value are reflected in the accompanying consolidated statements of comprehensive income.

In
connection with the April 2021 acquisition of the office building complex in Paris, €
120
 million (approximately $
140.9
 million)
of the purchase price was financed through a 
10
-year variable rate term loan. The Company entered into interest rate swap contracts related
to €
80
 million of the loan, effectively exchanging the variable interest rate to a fixed rate of approximately 
1.1
%. This
derivative instrument is recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements
of income.

Gains
and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives
not designated as hedges are included in loss (gain) on foreign currency in the accompanying consolidated statements of income.
Such gains and losses were immaterial for the three and nine months ended 
September 30, 2025
 and 
2024
, respectively.

All
derivative instruments are reported as either assets or liabilities on the consolidated balance sheet measured at fair value.
The fair value of interest rate swaps includes a liability position which is included in long-term debt on the accompanying consolidated balance sheet, and an asset position which is included in other assets on the accompanying balance sheet. The fair value of foreign currency forward exchange contracts at 
September 30, 2025
, resulted in a net asset and is included in other current assets on the accompanying consolidated balance sheet.

At

September 30, 2025
, the Company had foreign currency contracts in the form of forward exchange contracts with notional amounts of approximately 
USD $
60

million 
which all have maturities of less than

one year
.

Page 
10

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

7.

Leases:

The
Com
pany leases its offices and warehouses, vehicles, and certain office equipment, substantially all of which are classified as
operating leases. The Company currently has no material financing leases. The Company determines if an arrangement is a lease
at inception. Operating lease assets and obligations are recognized at the lease commencement date based on the present value
of lease payments over the lease term.

In
determining lease asset value, the Company considers fixed or variable payment terms, prepayments, incentives, and options to
extend or terminate, depending on the lease. Renewal, termination or purchase options affect the lease term used for determining
lease asset value only if the option is reasonably certain to be exercised. The Company generally uses its incremental borrowing
rate based on information available at the lease commencement date for the location in which the lease is held in determining
the present value of lease payments.

As
of 
September 30, 2025
, the weighted average remaining lease term was 
3.6
 years and the weighted average discount rate used to determine
the operating lease liability was 
3.1
%. Rental expense related to operating leases was $
1.8
 million
 and $
5.1
 million
 for the 
three and nine

months ended 
September 30, 2025
, 
respectively, 
as compared to $
1.6
 million and $
4.9
 million for the corresponding periods of the prior year
.
 Operating lease payments included in operating cash flows totaled $
5.0

million
 and $
4.4
 million
 for the 
nine months ended September 30, 2025
 and 
2024
, respectively, 
and noncash additions to operating lease assets totaled $
0.2

millio
n and $
1.2

million for the 
nine months ended September 30, 2025
 and 
2024
, respectively.

8.

Share-Based Payments:

The Company maintains a stock option program for key employees, executives and directors. The plans, all of which have been approved by shareholder vote, provide for the granting of both nonqualified and incentive options. Options granted under the plans typically have a 
six
-year term and vest over a 
four
 to 
five
-year period. The fair value of shares vested during the 
nine months ended September 30, 2025
 and 
2024
 aggregated 
$
0.02
 million
 and $
0.04
 million
, respectively. Compensation cost, net of estimated forfeitures, is recognized on a straight-line basis over the requisite service period for the entire award. Forfeitures are estimated based on historic trends. It is generally our policy to issue new shares upon exercise of stock options. 

The following table sets forth information with respect to nonvested options for the 
nine months ended September 30, 2025
:

Number of Shares

Weighted Average Grant-Date Fair Value

Nonvested options at January 1, 2025

118,650

$

30.02

Nonvested options granted

—

—

Nonvested options vested or forfeited

(
8,000

)

$

23.90

Nonvested options at 
September 30, 2025

110,650

$

30.46

Page 
11

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

Share-based payment expense decreased income before income taxes by $
0.37
 million and $
1.31
 million for the 
three and nine
 months ended 
September 30, 2025
 respectively, as compared to decreases of $
0.60
 million and $
1.77
 million for the 
three and nine
 months ended 
September 30, 2024
 respectively, and decreased income attributable to Interparfums, Inc. by $
0.26
 million
 and $
0.87
 million
 for the 
three and nine
 months ended 
September 30, 2025
 respectively, as compared to $
0.4
 million and $
1.17
 million for the corresponding periods of the prior year

.

The following table summarizes stock option information as of 
September 30, 2025
:

Shares

Weighted Average
 Exercise Price

Outstanding at January 1, 2025

248,430

$

103.00

Options forfeited

(
7,100

)

121.22

Options exercised

(
27,430

)

76.98

Outstanding at 
September 30, 2025

213,900

$

105.73

Options exercisable

103,250

$

82.55

Options available for future grants

499,495

As of 
September 30, 2025
, the weighted average remaining contractual life of options outstanding is 
2.8
 years (
1.0
 years for options exercisable); the aggregate intrinsic value of options outstanding and options exercisable is $
2.1
 million
 and $
2.1
 million
, respectively; and unrecognized compensation cost related to stock options outstanding aggregated $
2.7
 million.

Cash proceeds, tax benefits and intrinsic value related to stock options exercised during the 
nine months ended September 30, 2025
 and 
2024
 were as follows:

(In thousands)

September 30, 2025

September 30, 2024

Cash proceeds from stock options exercised

$

2,112

$

1,729

Tax benefits

205

272

Intrinsic value of stock options exercised

1,618

1,721

There were 
no
 options granted during the 
nine months ended September 30, 2025
 and 
September 30, 2024
.

Expected volatility is estimated based on the historic volatility of the Company’s common stock. The expected term of the option is estimated based on historical data. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of the grant of the option and the dividend yield reflects the assumption that the dividend payout as authorized by the Board of Directors maintain its current payout ratio as a percentage of earnings.

In March 2022, Interparfums SA, our 
72
% owned French subsidiary, approved a plan to grant an aggregate of 
88,400
 shares of its stock to all Interparfums SA employees and corporate officers having more than 
six months
 of employment at grant date, subject to certain corporate performance conditions. The corporate performance conditions were met and therefore in June 2025,
106,046
 shares, adjusted for stock splits, were distributed. 

The fair value of the grant had been determined based on the quoted stock price of Interparfums SA shares as reported by the Euronext on the date of grant. The aggregate cost of the grant of approximately $
4.2
 million
 was recognized as compensation cost on a straight-line basis over the requisite 
three and a quarter year
 service period.

Page 
12

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

In order to avoid dilution of the Company’s ownership of Interparfums SA, all shares distributed pursuant to this plan were pre-existing shares of Interparfums SA, purchased in the open market by Interparfums SA. As of 
September 30, 2025
 the Company acquired 
106,046
 shares at an aggregate cost of $
4.5
 million
.

All share purchases and issuances have been classified as equity transactions on the accompanying balance sheet.

9.

Net Income Attributable to Interparfums, Inc. Common Shareholders:

Net income attributable to Interparfums, Inc. per common share (“basic EPS”) is computed by dividing net income attributable to Interparfums, Inc. by the weighted average number of shares outstanding. Net income attributable to Interparfums, Inc. per share assuming dilution (“diluted EPS”), is computed using the weighted average number of shares outstanding, plus the incremental shares outstanding assuming the exercise of dilutive stock options using the treasury stock method.

The reconciliation between the numerators and denominators of the basic and diluted EPS computations is as follows:

Three months ended

Nine Months Ended

(In thousands)

September 30,

September 30,

2025

2024

2025

2024

Numerator:

Net income attributable to Interparfums, Inc.

$

65,809

$

62,259

$

140,289

$

140,130

Denominator:

Weighted average shares

32,113

32,026

32,114

32,030

Effect of dilutive securities:

Stock options

36

240

44

236

Denominator for diluted earnings per share

32,149

32,266

32,158

32,266

Earnings per share:

Net income attributable to

Interparfums, Inc. common shareholders:

Basic

$

2.05

$

1.94

$

4.37

$

4.37

Diluted

$

2.05

$

1.93

$

4.36

$

4.34

Not included in the above computations are the effect of antidilutive potential common shares which consist of outstanding options to purchase 
0.09

million shares of
 common stock for the

three and nine
 months ended 
September 30, 2025
 and 
0.05
 million shares of common stock 
for the 
three and nine
 months ended 
September 30, 2024
.

Page 
13

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

10.

Segment and Geographic Areas:

The Company manufactures and distributes 
one
 product line, fragrances and fragrance related products. The Company manages its business in 
two
 segments, European based operations and United States based operations. The European based operations, assets and business operations are primarily conducted in France, and include the results and assets of 
Interparfums
 Luxury Brands, 
Inc
., located in the United States. For United States based operations, assets and business operations are primarily conducted in the United States, and include the results and assets of 
Interparfums
 Italia 
Srl
, located in Italy. Both European based operations and United States based operations primarily represent the sale of prestige brand name fragrances.

Information on the Company’s operations by segments is as follows:

Three Months Ended September 30, 2025

Nine Months Ended September 30, 2025

United States

based operations

European

based operations

Total

United States

based operations

European

based operations

Total

Net sales

$

137,158

$

295,226

$

432,384

$

327,262

$

783,601

$

1,110,863

Eliminations (a)

—

(
2,805

)

(
2,805

)

—

(
8,529

)

(
8,529

)

137,158

292,421

429,579

327,262

775,072

1,102,334

Less: (b)

Cost of sales

57,448

100,426

134,020

261,951

Eliminations (a)

—

(
1,112

)

—

(
3,520

)

Segment gross margin

79,710

193,107

272,817

193,242

516,641

709,883

Less: (b)

Advertising and Promotion

21,458

44,054

52,748

133,133

Employee related costs

12,506

17,512

39,721

54,175

Royalties

10,286

24,432

24,559

65,925

Other segment items (c)

10,201

23,812

28,349

68,464

Segment income from operations

$

25,259

$

83,297

$

108,556

$

47,865

$

194,944

$

242,809

Reconciliation:

Interest expense

2,305

5,637

Loss on foreign currency

2,215

4,576

Interest and investment income

(
2,547

)

(
1,199

)

Other income

(
978

)

(
1,302

)

Income before income taxes

$

107,561

$

235,097

Page 
14

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated
Financial Statements

Three Months Ended September 30, 2024

Nine Months Ended September 30, 2024

United States

based operations

European

based operations

Total

United States

based operations

European

based operations

Total

Net sales

$

146,101

$

282,481

$

428,582

$

362,059

$

739,454

$

1,101,513

Eliminations (a)

—

(
3,953

)

(
3,953

)

—

(
10,692

)

(
10,692

)

146,101

278,528

424,629

362,059

728,762

1,090,821

Less: (b)

Cost of sales

59,632

95,462

151,465

249,279

Eliminations (a)

—

(
1,625

)

—

(
4,225

)

Segment gross margin

86,469

184,691

271,160

210,594

483,708

694,302

Less: (b)

Advertising and Promotion

23,416

43,414

55,312

126,230

Employee related costs

12,752

18,206

38,090

52,934

Royalties

10,686

23,334

26,181

62,052

Other segment items (c)

10,114

23,244

29,272

65,435

Segment income from operations

$

29,501

$

76,493

$

105,994

$

61,739

$

177,057

$

238,796

Reconciliation:

Interest expense

1,978

5,726

Loss on foreign currency

3,355

3,085

Interest and investment loss (income)

254

(
1,690

)

Other expense (income)

1

(
35

)

Income before income taxes

$

100,406

$

231,710

(a)

Eliminations of intercompany sales relate to European based operations products sold to United States based operations.

(b)

The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker.

(c)

Other segment items for each reportable segment include expenses for professional services, travel and entertainment, rent, warehousing, shipping, depreciation and amortization, and other selling, general and administrative costs.

Page 
15

INTERPARFUMS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

Other segment disclosures:

Three Months Ended September 30,

Nine Months Ended September 30,

2025

2024

2025

2024

Net income attributable to Interparfums, Inc.:

United States

$

20,822

$

24,263

$

39,045

$

49,015

Europe

46,257

39,869

105,001

95,966

Eliminations

(
1,270

)

(
1,873

)

(
3,757

)

(
4,851

)

$

65,809

$

62,259

$

140,289

$

140,130

Depreciation and amortization expense:

United States

$

1,736

$

1,701

$

5,169

$

5,128

Europe

4,809

4,480

13,667

13,073

$

6,545

$

6,181

$

18,836

$

18,201

Interest and investment (income) loss:

United States

$

(
1,048

)

$

2

$

(
1,788

)

$

(
2

)

Europe

(
1,499

)

252

589

(
2,376

)

Eliminations

—

—

—

688

$

(
2,547

)

$

254

$

(
1,199

)

$

(
1,690

)

Interest expense:

United States

$

489

$

195

$

1,093

$

1,350

Europe

1,816

1,783

4,544

5,064

Eliminations

—

—

—

(
688

)

$

2,305

$

1,978

$

5,637

$

5,726

Income tax expense:

United States

$

5,271

$

5,617

$

8,796

$

11,215

Europe

19,132

18,120

46,684

44,384

Eliminations

(
121

)

(
166

)

(
262

)

(
625

)

$

24,282

$

23,571

$

55,218

$

54,974

Additions to long-lived assets(a):

United States

$

166

$

171

$

708

$

1,109

Europe

5,099

874

45,040

2,630

$

5,265

$

1,045

$

45,748

$

3,739

(a)

Total long-lived assets include property, equipment and leasehold improvements, trademarks, licenses, and other intangible assets, and right-of-use assets.

September 30,

December 31,

2025

2024

Total Assets:

United States

$

381,871

$

352,139

Europe

1,199,593

1,073,326

Eliminations

(
16,814

)

(
14,204

)

$

1,564,650

$

1,411,261

Page 
16

INTERPARFUMS, INC. AND SUBSIDIARIES

I
tem 
2
:

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Information

Statements in this report which are not historical in nature are forward-looking statements. Although we believe that our plans, intentions and expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such plans, intentions or expectations will be achieved. In some cases, you can identify forward-looking statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or similar words. You should not rely on forward-looking statements because actual events or results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to, the risks and uncertainties discussed under the headings “Forward Looking Statements” and “Risk Factors” in Interparfums’ annual report on Form 10-K for the fiscal year ended 
December 31, 2024
, and the reports Interparfums files from time to time with the Securities and Exchange Commission (“SEC”). Interparfums does not intend to and undertakes no duty to update the information contained in this report.

Overview

We operate in the fragrance business, and manufacture, market and distribute a wide array of prestige fragrances and fragrance related products. We manage our business in 
two
 segments, European based operations and United States based operations. Certain prestige fragrance products are produced and marketed by our European based operations through our 
72
% owned subsidiary in Paris, Interparfums SA, which is also a publicly traded company as 
28
% of Interparfums SA shares trade on the Euronext.

We produce and distribute fragrance products through our European based operations primarily under license agreements with brand owners, and European based fragrance product sales represented approximately 
70
% and 
67
% of 
net
 sales for the 
nine months ended September 30, 2025
 and 
2024
, respectively. We have built a portfolio of prestige brands, which include Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas, 
Solférino
 and Van Cleef & Arpels, whose products are distributed in over 
120
 countries around the world. 

Through our United States based operations, we also produce and distribute fragrance and fragrance related products. United States based operations represented 
30
% and 
33
% of net sales for the 
nine months ended September 30, 2025
 and 
2024
, respectively. These fragrance products are sold primarily pursuant to license or other agreements with the owners of the Abercrombie & Fitch, Anna Sui, Donna Karan/DKNY, Emanuel Ungaro, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta and Roberto Cavalli brands.

Substantially all of our prestige fragrance brands are licensed from unaffiliated third parties, and our business is dependent upon the continuation and renewal of such licenses. With respect to the Company’s largest brands, we license the Jimmy Choo, Coach
, Montblanc
, GUESS, Lacoste, Donna Karan/DKNY, and Ferragamo brand names.

As a percentage of net sales for the nine months ended September 30, 2025 and 2024, product sales for the Company’s largest brands represented 
78
% and 
75
%, respectively, with a split by brand as follows:

Nine Months Ended

September 30,

2025

2024

Jimmy Choo

18

%

17

%

Coach

16

%

14

%

Montblanc

15

%

16

%

GUESS

11

%

11

%

Lacoste

8

%

6

%

Donna Karan/DKNY

6

%

7

%

Ferragamo

4

%

4

%

Page 
17

INTERPARFUMS, INC. AND SUBSIDIARIES

Quarterly sales fluctuations are influenced by the timing of new product launches as well as the third and fourth quarter holiday season. In certain markets where we sell directly to retailers, seasonality is more evident. We primarily sell directly to retailers in France, the United States, and Italy.

We grow our business in 
two
 distinct ways. First, we grow by adding new brands to our portfolio, through new licenses or other arrangements, or outright acquisitions of brands. Second, we grow through the introduction of new products and by supporting new and established products through advertising, merchandising and sampling, as well as phasing out underperforming products, so we can devote greater resources to those products with greater potential. The economics of developing, producing, launching and supporting products influence our sales and operating performance each year. The introduction of new products may have some cannibalizing effect on sales of existing products, which we take into account in our business planning.

Our business is not capital intensive, and it is important to note that we do not own manufacturing facilities. We act as a general contractor and source our needed components from our suppliers. These components are received and stored directly at our third party fillers or received at 
one
 of our distribution centers. For those components received at 
one
 of our distribution centers, based upon production needs, the components are subsequently sent to 
one
 of several third party fillers, which manufacture the finished product for us and then deliver them to 
one
 of our distribution centers.

As with any global business, many aspects of our operations are subject to influences outside our control. We believe we have a strong and well diversified brand portfolio with global reach and potential. As part of our strategy, we plan to continue to make investments behind fast-growing markets and channels to grow market share. 

Our reported net sales are impacted by changes in foreign currency exchange rates as approximately 
50
% of net sales of our European based operations are denominated in U.S. dollars, while almost all costs of our European based operations are incurred in euro. We address certain financial exposures through a controlled program of risk management that includes the use of derivative financial instruments and primarily enter into foreign currency forward exchange contracts to reduce the effects of fluctuating foreign currency exchange rates.

Recent Important Events

Please see our discussion of Recent Important Events, which is incorporated by reference to Note 
2
 to the Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q for the quarter ended 
September 30, 2025
.

Discussion of Critical Accounting Policies

Information regarding our critical accounting policies can be found in our 
2024
 Annual Report on Form 10-K filed with the SEC.

Page 
18

INTERPARFUMS, INC. AND SUBSIDIARIES

Results of Operations

Three and Nine
 Months Ended 
September 30, 2025
 as Compared to the 
Three and Nine
 Months Ended 
September 30, 2024

Net Sales:

Three Months Ended

Nine Months Ended

September 30,

September 30,

(in millions)

2025

2024

% Change

2025

2024

% Change

European based product sales

$

295.3

$

282.4

5

%

$

783.6

$

739.4

6

%

United States based product sales

137.1

146.1

(
6
)

%

327.2

362.1

10

%

Eliminations

(
2.8

)

(
3.9

)

n/a

(
8.5

)

(
10.7

)

n/a

$

429.6

$

424.6

1

%

$

1,102.3

$

1,090.8

1

%

*n/a = not applicable

Net sales for the 
three months ended September 30, 2025

increased

1
% from the 
three months ended September 30, 2024
. 
The average dollar/euro exchange rate for the current 
third quarter

was 1.17 compared to 1.10 in the 
third quarter

of

2024
, resulting in a positive foreign exchange impact on net sales of 2.2% in the

three months ended September 30, 2025

as compared to the prior year period. Net sales for the

nine months ended September 30, 2025 also

increased

1
% as compared to the

nine months ended September 30, 2024
.
 The average dollar/euro exchange rate for the nine months ended September 30, 2025 was 1.12 compared to 1.09 for the nine months ended September 30 2024, resulting in a positive foreign exchange impact on nets sales of 1.1% as compared to the prior year period. The discontinuation of the

Dunhill license decreased net sales for the nine months ended September 30, 2025 1% compared to the prior year period and a moderate impact in the current quarter compared to the prior year period.
 Overall organic growth on a year to date basis is 1.2% compared to the prior year period as consumers are being more selective and retailers are taking a cautious approach to inventory. 

For European based operations, sales in the 
three months ended September 30, 2025
 increased 5%, compared to the corresponding period of the prior year, driven by Jimmy Choo, Lacoste and Coach, which grew by 16%, 8% and 6%, respectively. These increases were driven by continued strong performance in these brands' established lines. Sales of Montblanc were down 2% in the third quarter, despite the recent release of the Montblanc 
Explorer Extreme
, resulting in a 6% decline for the 
nine months ended September 30, 2025
, as compared to the prior year period. We have further enhanced the brand with the launch of Montblanc 
Signature Elixir
 and believe it will gain traction through the balance of the year and into 2026. 

For United States based operations, sales in the 
three months ended September 30, 2025
 decreased 6% compared to the corresponding period of the prior year as a result of the discontinuation of the Dunhill license. With the phase-out of Dunhill fragrances completed in August of 2024, we expect minimal impact on a quarter-over-quarter comparison going forward. GUESS fragrance sales declined moderately by 3% in the 
three months ended September 30, 2025
, compared to the corresponding period of the prior year, due to a high base in the prior period third quarter and the phasing of innovation. The brand continues to perform well, and we believe the brand is poised for sales growth in the final quarter of the year. 
Donna

Karan
/DKNY fragrance sales declined 14% in the

three months ended September 30, 2025
, compared to the corresponding period of the prior year, due to robust growth levels achieved last year. Based on planned shipments through year end and the brand's popularity during the holiday season, particularly in the Americas, we believe the brand will grow in the final quarter of the year. 
Roberto Cavalli fragrance sales continue to benefit from increased focus, investment and innovation, growing 44% and 33% in the 
three and nine
 months ended 
September 30, 2025
, respectively, compared to the corresponding periods in the prior year. The brand continues to benefit from strong innovation, including the blockbuster launch of Roberto Cavalli 
Serpentine
 and a new duo, Just Cavalli 
Give Me Magic
. MCM sales rose by 6% in the 
third quarter
 of 2025 compared to the 
third quarter
 of 
2024
 with the continued success from the launch of the 
MCM Collection
. 
For the 
nine months ended September 30, 2025
, United States based operations sales decreased 10% on a reported basis and 6% on an organic basis, compared to the corresponding period of the prior year.

While the 2025 
third
 quarter saw only a slight overall increase, we are encouraged by our agility and pricing actions that are underway and expect to see the full impact of our efforts throughout the remainder of 2025 and through 2026. We continue to focus on our long-term strategy, innovative product development, and high service levels for our global retail and distribution partners. 
While the pace of growth in the fragrance market is starting to slow down, the power of our diverse brand portfolio, in combination with our agile operating model, should help us gain market share.

Page 
19

INTERPARFUMS, INC. AND SUBSIDIARIES

Net Sales to Customers by Region

Nine Months Ended

  (In millions)

September 30,

2025

2024

North America

$

414.8

$

397.4

Western Europe

288.5

281.0

Asia/Pacific 

140.8

154.2

Central and South America

99.6

88.9

Eastern Europe

81.1

76.8

Middle East and Africa

77.5

92.5

$

1,102.3

$

1,090.8

In the 
nine months ended September 30, 2025
, net sales in our largest market, North America, rose 4% as compared to the prior year period, followed by an increase in Western Europe of 3%. Our sales in Asia/Pacific decreased by 9% driven by distribution disruptions in South Korea and India in the current year. Our net sales in Eastern Europe were also robust, up 6% in the 
nine months ended September 30, 2025
 as compared to the prior year period when we faced temporary sourcing constraints. Central and South America net sales increased 12%. Middle East and Africa net sales declined 16% primarily related to a disproportionate impact from the exit of the Dunhill license due to its significant presence. Excluding the impact of Dunhill, Middle East and Africa net sales declined 7% due to the impacts of the conflicts in the region and a reduction in the number of doors in many markets that are now more focused on higher-end luxury fragrances. 

Gross Profit Margin

Three Months Ended

Nine Months Ended

    (in millions)

September 30,

September 30,

2025

2024

2025

2024

European based operations

Net sales

$

295.3

$

282.4

$

783.6

$

739.4

Cost of sales

100.5

95.5

262.0

249.3

Gross profit margin

$

194.8

$

186.9

$

521.6

$

490.1

Gross profit margin as a percentage of net sales

66.0

%

66.2

%

66.6

%

66.3

%

 United States based operations 

Net sales

$

137.1

$

146.1

$

327.2

$

362.1

Cost of sales

57.4

59.6

134.0

151.4

Gross profit margin

$

79.7

$

86.5

$

193.2

$

210.7

Gross profit margin as a percentage of net sales

58.1

%

59.2

%

59.0

%

58.2

%

The Company’s gross profit margin as a percentage of net sales was 
63.5
% 
and

64.4
% 
for the 
three and nine
 months ended 
September 30, 2025
 as compared to 
63.9
% 
and

63.6
% 
for the corresponding periods of the prior year.
 The Company continued to benefit from favorable segment, brand, and channel mix, 
in the nine months ended

September 30, 2025
 as compared to the prior year period. However, during the three months ended September 30, 2025 as compared to the prior year period, 
these favorable tailwinds as well as additional pricing actions that were taken at the back end of the quarter were not sufficient to offset the impacts of higher tariffs on our US imports, which represented $6 million.    

For European based operations, gross profit margin as a percentage of net sales was 
66.0
%

and

66.6
% 
for the 
three and nine
 months ended 
September 30, 2025
, respectively, as compared to 
66.2
% 
and

66.3
% 
for the corresponding period of the prior year.
 European based operations were negatively impacted by tariffs during the three 
months ended 
September 30, 2025
 as compared to the prior year period, offset by pricing increases in the United States and brand and channel mix.  During the nine months ended September 30, 2025, favorable 
channel mix resulted in the increase in gross profit as percentage of sales compared to the prior year period. 

Page 
20

INTERPARFUMS, INC. AND SUBSIDIARIES

For United States based operations, gross profit margin as a percentage of net sales was at 
58.1
%

and

59.0
% 
for the 
three and nine
 months ended 
September 30, 2025

respectively, as compared to

59.2
% and

58.2
% for the corresponding periods of the prior year.
 United States based operations saw a moderate decline due to the negative impact of tariffs as well as brand and channel mix in the three months ended September 30, 2025. The increase in the nine months ended September 30, 2025 was mainly driven by the discontinuation of Dunhill products, which were sold at lower margins in 2024 as is customary during sell-off periods. 

Generally, 
we do not bill customers for shipping and handling costs, which are
 included in selling, general and administrative expenses in the consolidated statements of income. As such, our Company’s gross profit may not be comparable to other companies, which may include these expenses as a component of cost of goods sold. 

Selling, general and administrative expenses

Three Months Ended

Nine Months Ended

     (In millions)

September 30,

September 30,

2025

2024

2025

2024

 European based operations 

Selling, general and administrative expenses

$

109.8

$

108.1

$

321.7

$

306.6

Selling, general and administrative expenses as a percentage of net sales

37.2

%

38.3

%

41.1

%

41.5

%

United States based operations

Selling, general and administrative expenses

$

54.5

$

57.0

$

145.4

$

148.9

Selling, general and administrative expenses as a percentage of net sales

39.7

%

39.0

%

44.4

%

41.1

%

The Company’s selling, general and administrative expenses as a percentage of 
net sales were
 38.2%
 and
 42.4
% for the

three and nine
 months ended 
September 30, 2025
 as 
compared to

38.9
% and

41.8
% for the

three and nine
 months ended 
September 30, 2024
. The decrease in the quarter was driven by the phasing of promotional and advertising activities. The increase in the first three quarters of the year was largely driven by increased overall spending on promotional and advertising activities and increased employee related costs, as well as negative foreign exchange impacts.    

For European based operations, selling, general and administrative expenses 
increased
 1.5% and 4.9% 
for the

three and nine
 months ended 
September 30, 2025
, respectively a
s compared to the corresponding periods of the prior year, and represented 
37.2
% and 41.1% of net sales for the 
three and nine
 months ended 
September 30, 2025
, as compared to 
38.3
% and 
41.5
% for the 
three and nine
 months ended 
September 30, 2024
. 
 A significant portion of our expense in European based operations are denominated in euros, resulting in costs as reported in USD. The decrease in selling, general and administrative expenses as a percentage of net sales in the third quarter and first nine months of the year was driven by the expiration of the 2022 free-share plan and distribution of shares in France in the second quarter resulting in the decrease in stock compensation amortization. 
For United States based operations, selling, general and administrative expenses 
decreased
 4.4% and 2.3% for the 
three and nine
 months ended 
September 30, 2025
 as compared to the corresponding periods of the prior year, and represented 39.7% and 44.4% of net sales for the 
three and nine
 months ended 
September 30, 2025
, as compared to 
39.0
% and 
41.1
% for the 
three and nine
 months ended 
September 30, 2024
. 
The increase in selling, general and administrative expenses as a percentage of net sales was largely driven by lower sales in 2025 with the discontinuation of Dunhill in 2024.

Promotion 
and advertising included in selling, general and administrative expenses aggregated $65.5

million and $185.9

million for the

three and nine
 months ended 
September 30, 2025
, respectively, as compared to

$
66.8

million and $
181.5

million for the corresponding periods of the prior year and represented
 15.3
% and
 16.9
% of net sales

for the

three and nine
 months ended 
September 30, 2025
, respectively, as compared to

15.7
% and

16.6
% for the corresponding periods of the prior year.

Promotion and advertising are integral parts of our industry, and we continue to invest heavily to support new pr
oduct launches and to build brand awareness. We are also investing in line with anticipated sell out by our retailers, which we believe are higher than our reported sales. We believe that our promotion and advertising efforts have a beneficial effect on sales. As such, the Company is focused on increasing promotional and advertising spending to support the continued success of our brands. Long term, we continue to anticipate that on a full year basis, promotion and advertising expenditures will aggregate approximately 
21
% of net sales.

Page 
21

INTERPARFUMS, INC. AND SUBSIDIARIES

Royalty expense included in 
selling, general and administrative expenses aggregated

$34.7

million and $90.5

million for
 the 
three and nine
 months ended 
September 30, 2025
, respectively, 
as compared to $
34.0

million and $
88.2

million for the corresponding periods of the prior year.

Royalty expense 
represented
 8.1
% and 8.2% 
of net sales for
 both the 
three and nine
 months ended 
September 30, 2025

as compared to

8.0
% and

8.1
% of net sales for
 the corresponding periods of the prior year.
 This increase was primarily driven by unfavorable brand mix.

Income from Operations

As a result of the above analysis regarding net sales, gross profit margins and selling, general and administrative expenses, our operating margins 
aggregated
 25.3
% and
 22.0
% for
 the 
three and nine
 months ended 
September 30, 2025
, respectively, 
as compared to

25.0
% and

21.9
% for
 the corresponding period of the prior year.

Other Income and Expense

Overall, other income and expense for the 
nine
 months ended 
September 30, 2025
, was a loss of $7.7 million as compared to a loss of $7.1 million in the corresponding prior year period. 
One
 of the main drivers is the impact of our gains and losses on foreign currency where we recognized a loss of $4.6 million in the first nine months of 
2025
 compared to $3.1 million in the first nine months of 
2024
. 
Another driver of this change is the impact of our gains and losses on marketable securities where we recorded 
a loss of $2.5 million in the first nine months of 
2025
 and 
a loss of $0.8 million in the first nine months 
of 
2024
. 
Changes in interest expense and interest income were favorable year-over-year with net interest expense of $1.8 million during the 
nine months ended September 30, 2025
 as compared to a net interest expense of $2.9 million in the prior year period. 

Interest expense is primarily related to the financing of brand and licensing acquisitions, as well as our headquarters in Paris. Long-term debt including current maturities aggregated $196.9 million and $
157.3
 million as of 
September 30, 2025
 and 
December 31, 2024
, respectively. Interest expense was $5.1 million in the 
nine months ended September 30, 2025
 compared to $5.3 million in the prior year period. 

We enter into foreign currency forward exchange contracts to manage exposure related to receivables from unaffiliated third parties denominated in a foreign currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Approximately 
50
% of net sales of our European based operations are denominated in U.S. dollars. Gains and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives not designated as hedges are included in (gain) loss on foreign currency on the accompanying consolidated income statements. Such gains and losses were immaterial in the 
three and nine
 months ended 
September 30, 2025
 and 
2024
.

Interest and investment income represents interest earned on cash and cash equivalents and short-term investments and realized and unrealized gains and losses on marketable equity securities. Interest income was $4.4 million in the 
nine months ended September 30, 2025
 compared to $2.7 million in the prior year period. 

Income Taxes

Our consolidated effective tax rate was 23.5% and 
23.7
% for the 
nine months ended September 30, 2025
 and 
2024
, respectively. The effective tax rate for European based operations was 24.4% and 
25.0
% for the 
nine months ended September 30, 2025
 and 
2024
, respectively. The decrease in taxes resulted from a $3 million favorable outcome to our mutual agreement procedure between the French and United States tax authorities in which we were able to reclaim the tax assessment paid in France in 2023. The gain was offset by a $1 million one-time tax assessment included in the tax expense as a result of a tax audit conducted for the 2022 and 2023 tax years. The effective tax rate for United States based operations was 20.0% for the 
nine months ended September 30, 2025
, as compared to 
19.8
% for the corresponding period of the prior year. Our effective tax rate for United States based operations differs from the 
21
% statutory rate in the United States as it is a blended rate across multiple jurisdictions, and takes into account benefits received from the exercise of stock options as well as deductions we are allowed for a portion of our foreign derived intangible income, slightly offset by state and local taxes. Other than as discussed above, we did not experience any significant changes in tax rates, and none were expected in jurisdictions where we operate.

Page 
22

INTERPARFUMS, INC. AND SUBSIDIARIES

Net Income

Three Months Ended

Nine Months Ended

    (In thousands)

September 30,

September 30,

2025

2024

2025

2024

Net income attributable to European based operations

$

63,726

$

54,445

$

144,590

$

132,572

Net income attributable to United States based operations

20,823

24,263

39,046

49,015

Eliminations

(
1,270

)

(
1,873

)

(
3,757

)

(
4,851

)

Net income

83,279

76,835

179,879

176,736

Less: Net income attributable to the noncontrolling interest

17,470

14,576

39,590

36,606

Net income attributable to Interparfums, Inc.

$

65,809

$

62,259

$

140,289

$

140,130

Net income attributable to Interparfums, Inc. was $
65.8
 million

and $
140.3

million for
 the 
three and nine
 months ended 
September 30, 2025
, respectively, as compared to $
62.3
 million 
and $
140.1

million for
 the corresponding period of the prior year.

Net income attributable to European based operations was $
63.7
 million

and $
144.6

million for
 the 
three and nine
 months ended 
September 30, 2025
, as compared to $
54.4
 million 
and $
132.6

million for
 the corresponding periods of the prior year,
 while net income attributable to United States based operations was $
20.8
 million

and $
39.0

million
 the 
three and nine
 months ended 
September 30, 2025
, as compared to $
24.3
 million 
and $
49.0

million
 the corresponding periods of the prior year. 
The significant fluctuations in net income for both European based operations and United States based operations are directly related to the previous discussions pertaining to changes in sales, gross margin, and selling, general and administrative expenses.

The noncontrolling interest arises from our 
72
% owned subsidiary in Paris, Interparfums SA, which is also a publicly traded company, as 
28
% of Interparfums SA shares trade on the Euronext. Net income attributable to the noncontrolling interest is directly related to the profitability of our European based operations and aggregated 
28
% of European based operations net income for both the 
nine months ended September 30, 2025
 and 
2024
. Net profit margins attributable to Interparfums, Inc. for the 
nine months ended September 30, 2025
 and 
2024
 aggregated 12.7% and 
12.8
%, respectively.

Liquidity and Capital Resources

Our conservative financial tradition has enabled us to amass significant cash balances. As of 
September 30, 2025
, we had $187.9 million in cash, cash equivalents and short-term investments, the majority of which are held in euros by our European based operations and is readily convertible into U.S. dollars. We have not experienced any liquidity issues to date, and do not expect any liquidity issues relating to such cash and cash equivalents and short-term investments.

As of 
September 30, 2025
, working capital aggregated $688.0 million. Approximately 77% of the Company’s total assets are held by European based operations, and approximately $294.4 million of trademarks, licenses and other intangible assets are also held by European based operations.

The Company is party to a number of licenses and other agreements for the use of trademarks and rights in connection with the manufacture and sale of its products expiring at various dates through 
2039
. In connection with most of these license agreements, the Company is subject to minimum annual advertising commitments, minimum annual royalties and other commitments. See Item 
8
. Financial Statements and Supplementary Data – Note 
11
 – Commitments in our 
2024
 annual report on Form 10-K, which is incorporated by reference herein. Future advertising commitments are estimated based on planned future sales for the license terms that were in effect at 
December 31, 2024
, without consideration for potential renewal periods and do not reflect the fact that our distributors share our advertising obligations.

The Company hopes to continue to benefit from its strong financial position to potentially acquire 
one
 or more brands, either on a proprietary basis or as a licensee. In July 2025, our 72% owned French subsidiary, Interparfums SA, signed an exclusive fragrance license agreement with Longchamp running through December 31, 2036. 
Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. The first launch is expected in 2027. 
In June 2025, our 
72
% owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Maison Goutal held by Amorepacific Europe, which is operating the Goutal brand under an existing license agreement that expires on 
December 31, 2025
, when Interparfums SA will begin commercial use of the fragrance brand. Additionally, in 
June
 2025, we renewed the Coach license agreement for an additional 
five
-year term, extending the license through June 30, 2031.

Page 
23

INTERPARFUMS, INC. AND SUBSIDIARIES

In December 2024, our 
72
% owned French subsidiary, Interparfums SA, obtained all Off-White brand names and registered trademarks for Class 
3
 fragrance and cosmetics products, subject to an existing license that expires on 
December 31, 2025
, when Interparfums SA will begin commercial use of the fragrance brands. Furthermore, in December 2024, we renewed the Van Cleef & Arpels license agreement for an additional 
nine
-year term, beginning January 1, 2025. In July 2023, we entered into a global licensing agreement for the creation, development and distribution of fragrances and fragrance related products under the Roberto Cavalli brand. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. This license took effect in July 2023, and we began shipping products in February 2024.

In December 2022, we entered into a long-term global licensing agreement for the creation, development and distribution of fragrances and fragrance related products under the Lacoste brand. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. This license took effect, and products began shipping in January 2024.

Cash provided by operating activities aggregated $68.4 million for the 
nine months ended September 30, 2025
 compared to $
49.7
 million for the 
nine months ended September 30, 2024
. For the 
nine months ended September 30, 2025
, working capital items used $133.9 million in cash from operating activities, as compared to $
147.0
 million in the 
2024
 period. F
rom a cash flow perspective, accounts receivables are up 23% from year end 
2024
. The balance is reasonable based on 
third
 quarter 
2025
 sales levels and seasonality of the business. Days' sales outstanding increased to 89 days, up from 83 days in the corresponding period of the prior 
year, 
driven by changes in our channel mix. Despite the increase, we are still seeing strong collection activity and do not anticipate any issues with collections of accounts receivable. 
From a cash flow perspective, inventory levels as of 
September 30, 2025
 decreased 5% from year end 
2024
 as we continue to drive inventory efficiencies. We are doing this by increasing conversion of raw materials into finished goods, resulting in finished goods making up 68% of our inventory levels at 
September 30, 2025
 as compared to 
63
% at 
September 30, 2024
. 

Cash flows provided by investing activities in 
2025
 are comprised of the net effect of purchases and sales of short-term investments. These investments consist of certificates of deposit with maturities greater than 
six
 months, marketable equity securities and other contracts. At 
September 30, 2025
, approximately $2.3 million of certificates of deposit contain penalties where we would forfeit a portion of the interest earned in the event of early withdrawal.

These proceeds were offset by the payment for capital expenditures during the year. In 
March 
2025, the Company paid approximately $19.7 million for the purchase of the 
Goutal
 trademark. Additionally, during the second and third quarters the Company purchased approximately $18.2 million of additional property in Paris attached to its French headquarters. 

Our business is not capital intensive as we do not own any manufacturing facilities. On a full year basis, we typically spend approximately $
5
 million on tools and molds, depending on our new product development calendar. Capital expenditures also include amounts for office fixtures, computer equipment, and industrial equipment needed at our distribution centers.

Cash flows used in financing activities in 
2025
 reflect issuances and repayments of debt to institutional lenders and payment of dividends to stockholders.

Our short-term financing requirements are expected to be met by available cash on hand at 
September 30, 2025
, and by short-term credit lines provided by domestic and foreign banks. The principal credit facilities for 
2025
 consist of $70.0 million unsecured revolving lines of credit provided by a consortium of domestic commercial banks and approximately $9.4 million 
(€8 
million)
 in credit lines provided by a consortium of international financial institutions. There was $9.4 million of short-term borrowings outstanding pursuant to these facilities as of 
September 30, 2025
 and $9.0 million outstanding as of 
September 30, 2024
.

In February 2024, the Board of Directors authorized an annual dividend of $
3.00
 per share. In February 2025, the Board of Directors further increased the annual dividend to $
3.20
 per share. The next quarterly cash dividend of $
0.80
 per share is payable on December 31, 2025, to shareholders of record on December 15, 2025.

We believe that funds provided by or used in operations can be supplemented by our present cash position and available credit facilities, so that they will provide us with sufficient resources to meet all present and reasonably foreseeable future operating needs.

Inflation rates in the United States and foreign countries in which we operate did not have a significant impact on operating results for the 
nine months ended September 30, 2025
; however, we have already started to see the impacts of tariffs on our cost structure and have adjusted our pricing accordingly, as such, we anticipate potential inflationary impacts in the last quarter of 2025 and beyond as our suppliers potentially adjust their pricing as well.

Page 
24

INTERPARFUMS, INC. AND SUBSIDIARIES

Item 
3
:

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

General

We address certain financial exposures through a controlled program of risk management that primarily consists of the use of derivative financial instruments. We primarily enter into foreign currency forward exchange contracts in order to reduce the effects of fluctuating foreign currency exchange rates. We do not engage in the trading of foreign currency forward exchange contracts or interest rate swaps.

Foreign Exchange Risk Management 

We periodically enter into foreign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign currency and to manage risks related to future sales expected to be denominated in a currency other than our functional currency. We enter into these exchange contracts for periods consistent with our identified exposures. The purpose of the hedging activities is to minimize the effect of foreign exchange rate movements on the receivables and cash flows of Interparfums SA, whose functional currency is the euro. All foreign currency contracts are denominated in currencies of major industrial countries and are with large financial institutions, which are rated as strong investment grade.

All derivative instruments are required to be reflected as either assets or liabilities in the balance sheet measured at fair value. Generally, increases or decreases in fair value of derivative instruments will be recognized as gains or losses in earnings in the period of change. If the derivative is designated and qualifies as a cash flow hedge, then the changes in fair value of the derivative instrument will be recorded in other comprehensive income.

Before entering into a derivative transaction for hedging purposes, we determine that the change in the value of the derivative will effectively offset the change in the fair value of the hedged item from a movement in foreign currency rates. Then, we measure the effectiveness of each hedge throughout the hedged period. Any hedge ineffectiveness is recognized in the income statement.

At 
September 30, 2025
, we had foreign currency contracts in the form of forward exchange contracts of approximately USD $60 million with maturities of less than 
one
 year. We believe that our risk of loss as the result of nonperformance by any of such financial institutions is remote.

Interest Rate Risk Management

We mitigate interest rate risk by monitoring interest rates, and then determining whether fixed interest rates should be swapped for floating rate debt, or if floating rate debt should be swapped for fixed rate debt.

Item 
4
.

CONTROLS AND PROCEDURES 

Evaluation of Disclosure Controls and Procedures 

Please see Item 
9
A. Controls and Procedures, “Evaluation of Disclosure Controls and Procedures” and “Remediation Plan,” as contained in our 
2024
 annual report on Form 10-K as filed with the SEC (“
2024
 Annual Report”), which are incorporated by reference in this quarterly report.
 As stated in our 
2024
 Annual Report, w
e believe that the actions set forth under “Remediation Plan,” will collectively remediate the material weaknesses identified.  However, our material weaknesses will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through testing, that the related controls are operating effectively. We will continue to monitor the design and effectiveness of these and other processes, procedures, and controls and will make any further changes management deems appropriate. The above disclosure is applicable to the evaluation of our disclosure controls and procedures for this 
third quarter
 of 
2025
. 

Changes in Internal Control Over Financial Reporting 

Except as described above, there has been no significant change in our internal control over financial reporting (as defined in Rule 
13
a-
15
(f) of the Securities Exchange Act of 
1934
) that occurred during the quarterly period covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Page 
25

INTERPARFUMS, INC. AND SUBSIDIARIES

Part II. Other Information

Item
1A. Risk Factors
.

Information regarding our Risk Factors can be found in our

2024

Annual Report on Form 10-K filed with the SEC. 

Item 
2
.

Unregistered Sales of Equity Securities and Use of Proceeds
.

Item (c).

In February 2025, our Board of Directors authorized the Company to continue repurchasing up to 
130,000
 shares throughout 2025, which was increased to 260,000 shares in April 2025.

Interparfums, Inc. Purchase of Common Stock

Period

Total Number of Shares Purchased

Average price paid per share

Total number of shares purchased as part of publicly announced plans or programs

Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs

July 1-31

0

n/a

0

240,000 shares

August 1-31

0

n/a

0

240,000 shares

September 1-30

52,872

$102.67

52,872

187,128 shares

Total

52,872

n/a

52,872

187,128 shares

Item 
5
. Other Information

Item (c). During the 
third
 quarter of 
2025
, 
no
 director or officer has adopted or 
terminated
 either any “
Rule 10b5-1 trading arrangement
” or “
non-Rule 
10
b
5
-
1
 trading arrangement
,” as such terms are defined in the applicable regulation.

Items 
1
. Legal Proceedings, 
1
A. Risk Factors, 
3
. Defaults Upon Senior Securities and 
4
. Mine Safety Disclosures, are omitted as they are either not applicable or have been included in Part I.

Page 
26

INTERPARFUMS, INC. AND SUBSIDIARIES

Item
6. Exhibits. 

The
following documents are filed herewith:

Exhibit
    No.

Description

Page
    Number

31.1

Certifications required by Rule 13a-14(a) of Chief Executive Officer

29

31.2

Certifications required by Rule 13a-14(a) of Chief Financial Officer and Principal Accounting Officer

30

32.1

Certification required by Section 906 of the Sarbanes-Oxley Act of Chief Executive Officer

31

32.2

Certification required by Section 906 of the Sarbanes-Oxley Act of Chief Financial Officer and Principal Accounting Officer

31

101

Interactive
    data files

Page 
27

INTERPARFUMS, INC. AND SUBSIDIARIES

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized on the 5th day of November 2025.

INTERPARFUMS, INC.

By:

/s/ Michel Atwood

Chief Financial Officer

Page 
28